 |
SEOUL, South Korea, May 20, 2026 /PRNewswire/ — Hyundai Bioscience announced on May 19th that it can supply clinical trial doses of its broad-spectrum antiviral drug XAFTY® in response to growing global concern over infectious disease outbreaks caused by Ebola and hantavirus.
Hyundai Bioscience said that if the World Health Organization (WHO) or countries affected by infectious disease outbreaks request support for XAFTY®, it can immediately provide products currently in stock.
According to the company, niclosamide, the main ingredient of XAFTY®, has previously been reported to have inhibitory effects against Ebola and hantavirus.
The company stated, “In the ongoing Phase 2 clinical trial of XAFTY® for dengue fever in Vietnam, no adverse events have been reported so far,” and claimed that “in a situation where two viruses are spreading simultaneously, XAFTY® could serve as an effective alternative.”
Hyundai Bioscience added that, as a member of the Medical CBRN Defense Consortium (MCDC), a U.S. Department of Defense-supported consortium, it will actively cooperate in responding to international public health crises.
CONTACT：
Jason Kim
[email protected]
(562) 964-3910
ข่าวที่เกี่ยวข้อง
- IBM Unveils Its Most Advanced Quantum Computer in Chicago, Marking a Milestone for Illinois’s Quantum Future
- AMTD IDEA, AMTD Digital and TGE Jointly Announce the Injection of Four Premium Hotel Assets into TGE
- U Power Reports Unaudited Financial Results for the First Half of 2026
- VS Pharmtech Boosts Cancer Treatment Efficacy Without Adding Toxicity
